Effect of Topical Phenylephrine 2.5% on EVP in Normal Human Eyes

• Status: Completed
• Trial end date: 2018-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Phenylephrine hydrochloride ophthalmic solution is an alpha-1 adrenergic receptor agonist commonly used topically for dilation prior to ocular fundus examination. In the eye, phenylephrine acts locally as a potent vasoconstrictor and mydriatic by constricting ophthalmic blood vessels and the radial dilator muscle of the iris. Episcleral venous pressure (EVP) is a determinant of intraocular pressure (IOP) and can be measured non-invasively by venomanometry. Since phenylephrine is a vasoconstrictor, it may affect episcleral venous tone, but the effect on EVP is unknown. Understanding the physiology of episcleral veins helps us in better understanding of pathophysiology of glaucoma.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Mayo Clinic
• Treatments: Oxymetazoline; Phenylephrine

Criteria

Inclusion Criteria:

• Any self-declared ethno-racial category.

• Medically healthy subjects.

• Subjects with two healthy eyes.

• Intraocular pressure (IOP) less than 22 mmHg in each eye.

• Best-corrected visual acuity (BCVA) in each eye 20/50 or better.

• Open angles in both eyes.

• Contact lens wear stopped at least 3 days prior to study, and during the study.

• Ability to cooperate for examinations required for study.

Exclusion Criteria:

• Chronic or acute ophthalmic diseases including glaucoma, wet type macular degeneration, uveitis and clinically significant cataract.

• Evidence of ocular infection, inflammation, clinically significant blepharitis or conjunctivitis.

• Cornea pathologic changes preventing reliable measurement.

• Narrow anterior chamber angle.

• Previous intraocular surgeries, laser procedures, and intravitreal injections.

• Previous corneal refractive surgeries.

• Myopia greater than -6.00 D spherical equivalent.

• Hyperopia greater than +2.00 D spherical equivalent.

• Lack of suitable episcleral vein for measurement.

• Ocular trauma within the past 6 months.

• Ocular infection or ocular inflammation in the past 3 months.

• Ocular medication of any kind within 30 days of study visit.

• Known hypersensitivity to Phenylephrine or topical anesthetic medication.

• Severe hypertension: Systolic blood pressure greater than 180 mmHg and/or diastolic blood pressure greater than 105 mmHg.

• A known history of ischemic heart disease (angina or myocardial infarction), cerebrovascular accidents, cardiac arrhythmias, cerebral or aortic aneurysms.

• Uncontrolled diabetes mellitus.

• Uncontrolled hyperthyroidism.

• Use of some systemic medications within 30 days prior to study including: β-adrenergic antagonists, α-adrenergic agonists and antagonists, calcium channel blockers, diuretics, vasodilators, monoamine oxidase inhibitors, and systemic steroids.

• Participation in any interventional study within the past 30 days prior to study visit.

• Women who are pregnant.